Biomarker Qualification for Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: Theory and Practice
Annals of Neurology · 2024
DOI: 10.1002/ana.26860 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Neurology, 2024. Verfasst von Michael Benatar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Objective
To explore whether the utility of neurofilament light chain (NfL), as a biomarker to aid amyotrophic lateral sclerosis (ALS) therapy development, would be enhanced by obtaining formal qualification from the US Food and Drug Administration for a defined context‐of‐use.
Methods
Consensus discussion among academic, industry, and patient advocacy group representatives.
Results
A wealth of scientific evidence supports the use of NfL as a prognostic, response, and potential safety biomarker in the broad ALS population, and as a risk/susceptibility biomarker among the subset of SOD1 pathogenic variant carriers. Although NfL has not yet been formally qualified for any of these contexts‐of‐use, the US Food and Drug Administration has provided accelerated approval for an SOD1‐lowering antisense oligonucleotide, based partially on the recognition that a reduction in NfL is reasonably likely to predict a clinical benefit.
Interpretation
The increasing incorporation of NfL into ALS therapy development plans provides evidence that its utility—as a prognostic, response, risk/susceptibility, and/or safety biomarker—is already widely accepted by the community. The willingness of the US Food and Drug Administration to base regulatory decisions on rigorous peer‐reviewed data‐absent formal qualification, leads us to conclude that formal qualification, despite some benefits, is not essential for ongoing and future use of NfL as a tool to aid ALS therapy development. Although the balance of considerations for and against seeking NfL biomarker qualification will undoubtedly vary across different diseases and contexts‐of‐use, the robustness of the published data and careful deliberations of the ALS community may offer valuable insights for other disease communities grappling with the same issues. ANN NEUROL 2024;95:211–216
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA.
- Department of Neurology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
- CReATe Biomarkers External Advisory Committee.
- Denali Therapeutics, South San Francisco, CA, USA.
- Ionis Pharmaceuticals, Carlsbad, CA, USA.
- Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.
ORCID-Profile: Michael Benatar, Lyle W Ostrow, Robert Bowser
Förderung
- NINDS NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Benatar, M., Ostrow, L. W., Lewcock, J. W., Bennett, F., Shefner, J., Bowser, R., Larkin, P., Bruijn, L., & Wuu, J. (2024). Biomarker Qualification for Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: Theory and Practice. Annals of Neurology. https://doi.org/10.1002/ana.26860
Vancouver
Benatar M, Ostrow LW, Lewcock JW, Bennett F, Shefner J, Bowser R, et al. Biomarker Qualification for Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: Theory and Practice. Annals of Neurology. 2024. doi:10.1002/ana.26860
BibTeX
@article{Benatar2024,
author = {Benatar, Michael and Ostrow, Lyle W and Lewcock, Joseph W and Bennett, Frank and Shefner, Jeremy and Bowser, Robert and Larkin, Paul and Bruijn, Lucie and Wuu, Joanne},
title = {Biomarker Qualification for Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: Theory and Practice},
journal = {Annals of Neurology},
year = {2024},
doi = {10.1002/ana.26860}
}
EUVIMED